Trial · NCT03921411
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Nemolizumab Serum Concentrations at Week 1-2 | Nemolizumab | 6478.8 | Standard Deviation 2393.11 | nanogram per milliliter (ng/mL) | |
| Nemolizumab Serum Concentrations at Week 4 | Nemolizumab | 2935.3 | Standard Deviation 1029.41 | ng/mL | |
| Nemolizumab Serum Concentrations at Week 8 | Nemolizumab | 3292.3 | Standard Deviation 2017.83 | ng/mL | |
| Nemolizumab Serum Concentrations at Week 12 | Nemolizumab | 3221.6 | Standard Deviation 1781.15 | ng/mL | |
| Nemolizumab Serum Concentrations at Week 16 | Nemolizumab | 3010.0 | Standard Deviation 1131.81 | ng/mL | |
| Nemolizumab Serum Concentrations at Week 24 | Nemolizumab | 473.9 | Standard Deviation 333.72 | ng/mL | |
| Apparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab | Nemolizumab | 0.325 | Standard Deviation 0.153 | liter/day (L/day) | |
| Apparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab | Nemolizumab | 7.15 | Standard Deviation 2.24 | liter | |
| Population Lag Time (Tlag) | Nemolizumab | 1.0728 | Standard Deviation 0 | hours | |
| First Order Constant of Absorption (ka) | Nemolizumab | 0.402 | Standard Deviation 0.145 | 1/day | |
| Maximum Observed Serum Concentration (Cmax) of Nemolizumab | Nemolizumab | 5975.5 | Standard Deviation 2175.2 | ng/mL | |
| Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab | Nemolizumab | 5.862 | Standard Deviation 1.669 | days | |
| Trough Serum Concentration (Ctrough) of Nemolizumab at Week 4 | Nemolizumab | 3271.859 | Standard Deviation 1268.612 | ng/mL | |
| Trough Serum Concentration (Ctrough) of Nemolizumab at Week 8 | Nemolizumab | 3056.496 | Standard Deviation 1367.884 | ng/mL | |
| Trough Serum Concentration (Ctrough) of Nemolizumab at Week 12 | Nemolizumab | 2886.796 | Standard Deviation 1441.998 | ng/mL | |
| Trough Serum Concentration (Ctrough) of Nemolizumab at Week 16 | Nemolizumab | 2981.792 | Standard Deviation 1166.871 | ng/mL | |
| Area Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w) | Nemolizumab | 144046.235 | Standard Deviation 50800.805 | nanogram*day per milliliter (ng*day/mL) | |
| Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w) | Nemolizumab | 284397.143 | Standard Deviation 97105.285 | ng*day/mL | |
| Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w) | Nemolizumab | 411707.857 | Standard Deviation 142851.408 | ng*day/mL | |
| Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w) | Nemolizumab | 549489.167 | Standard Deviation 184483.765 | ng*day/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03921411/results